Bio-Thera doses first patient in Phase 1 trial of CD25-targeting ADC
Tweet Send to a Friend
Bio-Thera Solutions, Ltd. (SH: 688177) announced that the first patient has been dosed in a Phase 1 clinical study evaluating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


